Skip to content

Serotonin: all studies

Page 280 of 400: studies 2,791 to 2,800 of 3,999, newest first. Back to the serotonin overview

Research

Potential Therapeutic Effects of Psilocybin: A Systematic Review.

Cureus October 1, 2022 Dev B Goel, Sarju Zilate 24 citations

Psilocybin is a plant alkaloid that is derived from precursors of tryptamine and is present in many different types of mushrooms. It has been utilized by indigenous peoples of Central and South America for centuries in a ceremonial setting to promote spiritual experiences. Indigenous societies have long employed psilocybin and other 5-HT 2A agonist classic psychedelics in their rites. They were...

Self-Transcendent Positive Emotions as a Potential Mechanism Underpinning the Effects of Meaningful Psychedelic Experiences on Connectedness to Nature

Ecopsychology September 27, 2022 Katie Newton, Sam G. Moreton

Emerging research suggests that the use of serotonergic psychedelics may increase feelings of connection with the natural world. However, little is known about why this might be the case. Psychedelics often elicit self-transcendent positive emotions (STPE), and recent work has provided preliminary evidence suggesting that several of these emotions may have a causal influence on people's...

White matter alterations in chronic MDMA use: Evidence from diffusion tensor imaging and neurofilament light chain blood levels

NeuroImage: Clinical September 19, 2022 Josua Zimmermann, Nicole Friedli, Francesco Bavato et al. 14 citations

3,4–Methylenedioxymethamphetamine (MDMA, “Ecstasy”) is a serotonin- and noradrenaline-releasing substance, currently among the most widely used illicit substances worldwide. In animal studies, repeated exposure to MDMA has been associated with dendritic but also axonal degeneration in the brain. However, translation of the axonal findings, specifically, to humans has been repeatedly questioned...

DOI: 10.1016/j.nicl.2022.103191 (opens in new tab) Full text (opens in new tab) MDMA Neurotoxicity Axonal neuropathology White matter +2

Psychedelics and mindfulness: A systematic review and meta-analysis

Journal of Psychedelic Studies September 16, 2022 Chelsea Radakovic, Ratko Radaković, Guy Peryer et al. 23 citations

Abstract Background and aims The benefits of classic serotonergic psychedelics (e.g. psilocybin, LSD, DMT, ayahuasca) are becoming more widely known with the resurgence in research in the past decade. Furthermore, the benefits of mindfulness are well documented. However, no systematic reviews have examined linkage of mindfulness and psychedelics use. The aim of this systematic review is to...

Ketamine Pharmacodynamics Entangled: Reply

Anesthesiology September 12, 2022 Albert Dahan, Erik Olofsen, Thomas K. Henthorn et al. 3 citations

We thank Bowdle et al.1 for their interest in our article,2 and for the important issue they raise, paraphrased as follows: what is the best anthropocentric description of the "mind-altering" effects of a heterogeneous group of compounds and drugs that act at the brain and cause significant changes in mental state. The group of drugs that we are referring to includes N-methyl-d-aspartate (NMDA)...

DOI: 10.1097/aln.0000000000004350 (opens in new tab) Ketamine Pharmacodynamics Pharmacology Anesthesia

Classic psychedelics: past uses, present trends, future possibilities

September 8, 2022 Adam Safron, Matthew Johnson 5 citations preprint

Here we consider psychedelics with respect to their mechanisms of action, use, and implications for our understandings of brain and mind. This review is somewhat nontraditional in its scope, with discussions of both basic facts as well as theoretical speculations. We chose this approach given the unique historical context we find ourselves in at present. While we have decades of investigations...

Microdosing psilocybin for chronic pain: a case series

Pain September 5, 2022 Matthew Lyes, Joel Castellanos, Timothy Furnish et al. 55 citations

Abstract Psychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end of life anxiety, and addiction when administered in hallucinogenic doses and coupled with psychotherapy. Although it has been suggested that similar high-dose protocols may help chronic pain conditions, there are few published clinical trials of...

Natural language signatures of psilocybin microdosing.

Psychopharmacology September 1, 2022 Camila Sanz, Federico Cavanna, Stephanie Müller et al. 1 citation

Serotonergic psychedelics are being studied as novel treatments for mental health disorders and as facilitators of improved well-being, mental function, and creativity. Recent studies have found mixed results concerning the effects of low doses of psychedelics ("microdosing") on these domains. However, microdosing is generally investigated using instruments designed to assess larger doses of...

To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.

Experimental and Clinical Psychopharmacology September 1, 2022 Julie A E Christensen, David C. Fipps, J Michael Bostwick 4 citations

Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis,...